Skip to main content
Erschienen in: Investigational New Drugs 1/2019

03.07.2018 | SHORT REPORT

Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein

verfasst von: Takahisa Kawamura, Haruyasu Murakami, Haruki Kobayashi, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Masahiro Endo, Toshiaki Takahashi

Erschienen in: Investigational New Drugs | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Summary

The recent approval of anaplastic lymphoma kinase (ALK) inhibitors for the treatment of ALK-rearranged non-small cell lung cancer (NSCLC) has dramatically transformed cancer therapy. However, leptomeningeal metastases (LM) are frequent and often devastating complications of ALK-rearranged NSCLC, and treatment against LM remains challenging. Herein we report a case of a 19-year-old male diagnosed with ALK-rearranged NSCLC with LM. He experienced heavy treatment before introduction of alectinib therapy, which continued for approximately 5.5 years with marked efficacy. However, he experienced recurrence of a bulbar metastasis after discontinuation of alectinib. Reintroduction of standard-dose alectinib therapy resolved the lesion again. Our findings suggest that ALK-tyrosine kinase inhibitor therapy should be continued in patients showing a long-term complete response, unless intolerable toxicities are present, and that rechallenge treatment with alectinib may represent a therapeutic option for central nervous system metastases.
Literatur
1.
Zurück zum Zitat Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390:29–39CrossRef Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390:29–39CrossRef
2.
Zurück zum Zitat Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators (2017) Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer. N Engl J Med 377:829–838CrossRefPubMed Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators (2017) Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer. N Engl J Med 377:829–838CrossRefPubMed
3.
Zurück zum Zitat Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H (2014) Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74:1023–1028CrossRefPubMed Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H (2014) Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74:1023–1028CrossRefPubMed
4.
Zurück zum Zitat Gainor JF, Ou SH, Logan J et al (2013) The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 8:1570–1573CrossRefPubMed Gainor JF, Ou SH, Logan J et al (2013) The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 8:1570–1573CrossRefPubMed
5.
Zurück zum Zitat Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK, Shih HA, Shaw AT (2016) Alectinib dose escalation Reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer relapsing on standard dose Alectinib. J Thorac Oncol 11:256–260CrossRefPubMed Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK, Shih HA, Shaw AT (2016) Alectinib dose escalation Reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer relapsing on standard dose Alectinib. J Thorac Oncol 11:256–260CrossRefPubMed
Metadaten
Titel
Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein
verfasst von
Takahisa Kawamura
Haruyasu Murakami
Haruki Kobayashi
Kazuhisa Nakashima
Shota Omori
Kazushige Wakuda
Akira Ono
Hirotsugu Kenmotsu
Tateaki Naito
Masahiro Endo
Toshiaki Takahashi
Publikationsdatum
03.07.2018
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 1/2019
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-018-0633-6

Weitere Artikel der Ausgabe 1/2019

Investigational New Drugs 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.